Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
02 2019
Historique:
received: 08 06 2018
accepted: 20 09 2018
pubmed: 22 9 2018
medline: 6 5 2020
entrez: 22 9 2018
Statut: ppublish

Résumé

Asparaginase is an important drug for the treatment of leukemias. However, anti-asparaginase antibodies often develop, which can decrease asparaginase drug levels and increase the risk of relapse. The aim of this study is to identify the immunoglobulin isotypes and receptors responsible for asparaginase hypersensitivities. Mice immunized with asparaginase developed anti-asparaginase IgG1 and IgE antibodies, and challenging the sensitized mice with asparaginase induced severe hypersensitivity reactions. Flow cytometry analysis indicated that macrophages/monocytes, neutrophils, and basophils bind asparaginase

Identifiants

pubmed: 30237274
pii: haematol.2018.199448
doi: 10.3324/haematol.2018.199448
pmc: PMC6355496
doi:

Substances chimiques

Antineoplastic Agents 0
Immunoglobulin G 0
Receptors, IgE 0
Receptors, IgG 0
Immunoglobulin E 37341-29-0
Asparaginase EC 3.5.1.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-329

Subventions

Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142665
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216815
Pays : United States

Informations de copyright

Copyright © 2019 Ferrata Storti Foundation.

Références

J Allergy Clin Immunol. 2018 Jun;141(6):2121-2131
pubmed: 29655584
Cancer. 1970 Feb;25(2):253-78
pubmed: 4905153
Adv Exp Med Biol. 1999;457:621-9
pubmed: 10500842
J Allergy Clin Immunol. 2017 Jan;139(1):269-280.e7
pubmed: 27246523
Proc Soc Exp Biol Med. 1957 Aug-Sep;95(4):625-7
pubmed: 13465749
Cancer. 1976 Jan;37(1):220-8
pubmed: 1061636
J Pharmacol Exp Ther. 2015 Mar;352(3):541-51
pubmed: 25573198
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
J Immunol. 2005 Jun 15;174(12):7716-24
pubmed: 15944273
Blood. 2002 Mar 15;99(6):1986-94
pubmed: 11877270
Haematologica. 2016 Mar;101(3):279-85
pubmed: 26928249
J Clin Invest. 2006 Mar;116(3):833-41
pubmed: 16498503
Leuk Lymphoma. 2014 Jan;55(1):92-6
pubmed: 23581640
Cancer Chemother Pharmacol. 2004 Mar;53(3):204-8
pubmed: 14634792
J Clin Oncol. 2000 Apr;18(7):1525-32
pubmed: 10735901
J Clin Invest. 2002 Oct;110(7):1021-7
pubmed: 12370280
Cancer Res. 1989 Aug 1;49(15):4363-8
pubmed: 2743326
J Allergy Clin Immunol. 2009 Apr;123(4):895-9
pubmed: 19081614
Leukemia. 1998 Oct;12(10):1527-33
pubmed: 9766495
Immun Inflamm Dis. 2015 Sep;3(3):280-8
pubmed: 26417442
J Allergy Clin Immunol. 2002 Apr;109(4):658-68
pubmed: 11941316
Leukemia. 2012 Nov;26(11):2303-9
pubmed: 22484422
Cancer. 2011 Jan 15;117(2):238-49
pubmed: 20824725
Toxicol Lett. 2016 Feb 3;242:53-59
pubmed: 26626100
J Immunol. 1955 May;74(5):387-90
pubmed: 14367826
J Allergy Clin Immunol. 1998 Mar;101(3):429-31
pubmed: 9525466
J Allergy Clin Immunol. 2018 May;141(5):1711-1725.e9
pubmed: 29454836
Leukemia. 2008 Sep;22(9):1665-79
pubmed: 18580955
Blood. 2015 Jul 2;126(1):69-75
pubmed: 25987655
Immunity. 2008 Apr;28(4):581-9
pubmed: 18342553
J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26
pubmed: 15087948
J Immunol. 1983 Nov;131(5):2178-83
pubmed: 6195255
Leukemia. 1998 Apr;12(4):619-22
pubmed: 9557622
Blood. 2012 Feb 16;119(7):1658-64
pubmed: 22117041
J Clin Invest. 1997 Mar 1;99(5):901-14
pubmed: 9062348
J Immunol Methods. 2000 May 26;239(1-2):75-83
pubmed: 10821949
J Immunol. 2014 Feb 15;192(4):1480-90
pubmed: 24442430
Cell. 1998 May 29;93(5):885-96
pubmed: 9630231
J Nucl Med. 2017 Feb;58(2):214-220
pubmed: 27493268
Blood. 2014 Aug 21;124(8):1266-76
pubmed: 24970932
Rev Bras Hematol Hemoter. 2017 Jul - Sep;39(3):202-209
pubmed: 28830598
Pediatr Blood Cancer. 2011 Oct;57(4):569-77
pubmed: 21360654

Auteurs

Sanjay Rathod (S)

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, PA.

Manda Ramsey (M)

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, PA.

Mary V Relling (MV)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.

Fred D Finkelman (FD)

Department of Internal Medicine, Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine and the Division of Immunobiology, Cincinnati Children's Hospital Medical Center, OH, USA.

Christian A Fernandez (CA)

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, PA chf63@pitt.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH